STTK: shattucklabs.com Company Value to Net Income
The efficiency of the GADLEN platform in creating bispecific drugs determines the success of Shattuck Labs, Inc. (STTK), which is confirmed by the market trend on GURU.Markets, where the indicator stands at -7.70. Development is conducted in the US, ensuring operational stability and protection from external political conflicts. High R&D expenditures and patent protection create a significant barrier to entry for new players.
%20P%2FE%20Multiple&width=1200&height=400&colorIndex=0&v=mwczyyub.rjb-7czcsu8&start=20220704&end=20261112&filename=GURU_Markets_-_STTK_-_Shattuck-Labs-Inc._-_PE-Multiple "STTK: Shattuck Therapeutics Business Payback Period 07/04/2022 - 11/12/2026 | 👁️GURU.Markets👁️")
Analytical breakdowns for Shattuck Labs Inc (STTK)
- price and consensus price forecast:
- market capitalization information:
- balance sheet net asset value indicators:
- debt and solvency information:
Total Debt to Equity Ratio Shattuck Labs, Inc.|STTK - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Shattuck Therapeutics|STTK - Company Debts|Debt to Book Value Ratio Shattuck Labs, Inc.|STTK - Company Long-Term Debts|Short-Term Debt Shattuck Labs|Interim Coverage Ratio shattucklabs.com
- earnings and market multiples details:
STTK - Net Profit|Expected Net Income Shattuck Labs, Inc.|STTK - P/E Multiple|Forward P/E Multiple Shattuck Therapeutics|STTK - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Shattuck Labs, Inc.|STTK - Operating profit before deduction of amortization|Earnings per share for the last four quarters Shattuck Labs|STTK - Net earnings per share for the last 12 months|Quarterly EPS earnings growth shattucklabs.com|STTK - Earnings growth in current year|Expected earnings per share growth for next year Shattuck Labs, Inc.
Comprehensive company analysis:shattucklabs.com STTK
Implementing the ARC platform for the development of bifunctional cancer therapies requires colossal investment, making the analysis of the price-to-earnings ratio critical for assessing the business value of Shattuck Labs, Inc. (STTK). This ratio measures the market's willingness to pay a premium for future growth; therefore, a decline in the reported P/E ratio signals a discount that could serve as either an entry point or a sign of market skepticism.
Key competitors
P/E Multiple argenx.com|Price to Earnings Ratio BNTX (BioNTech)|ABVX (ABIVAX) - Company Value to Net Income|P/E Multiple ADMA (ADMA Bio)|Business Payback Period Protagonist Corp (PTGX)|IMVT - Price to Earnings Ratio|kiniksa.com (KNSA) - Price to Earnings Ratio|Grifols (GRFS) - Price to Earnings Ratio|Price to Earnings Ratio Adaptive Biotech|Price to Earnings Ratio CLDX|P/E Multiple Aurinia Corp|Price to Earnings Ratio BioCryst (BCRX)|veratx.com - Price to Earnings Multiple|P/E Multiple DNTH (Dianthus Therapeutics, Inc.)|Pharvaris NV (PHVS) - Market Cap to Earnings|ABCL - Price to Earnings Ratio|Business Payback Period Tourmaline TRML|PGEN: P/E Multiple|pharming.com - Company Value to Net Income|NKTR (Nektar Therapeutics Inc.) - P/E Multiple|P/E Multiple Upstream Bio, Inc.|Price to Earnings Ratio ZBIO (Zenas Biopharma, Inc.)|Market Price to Net Income Ratio IMNM|Gossamer Bio, Inc. - Price to Earnings Ratio|Market Price to Net Income Ratio KALV (kalvista.com)|SEPN: Price to Earnings Ratio|PVLA - P/E Multiple|SVRA: P/E Multiple|Price to Earnings Ratio Rigel Corp|Price to Earnings Ratio AnaptysBio, Inc.|P/E Multiple astriatx.com|Price to Earnings Ratio ENGN (enGene)|RAPT (RAPT Therapeutics Inc.) - Company Value to Net Income|Price to Earnings Ratio Aerovate Therapeutics JBIO|Aclaris Therapeutics, Inc - Price to Earnings Ratio|Kyverna Therapeutics - P/E Multiple|TLSA - P/E Multiple|CABA: P/E Multiple|VTYX (Ventyx Biosciences Inc.) - Price to Earnings Ratio|Price to Earnings Ratio Theratechnologies Inc|Avalo Therapeutics Inc (AVTX) - Business Payback Period|Price to Earnings Ratio ELDN (Eledon Pharmaceuticals)|AGEN (agenusbio.com) - Company Value to Net Income|P/E Multiple CLYM (Climb Bio)|Business Payback Period Zura Bio Ltd (ZURA)|ATYR - Price to Earnings Ratio|ADAG (Adagene) - Price to Earnings Multiple|IMA: P/E Multiple|Price to Earnings Ratio Equillium|Price to Earnings Ratio CNTB|Immunic Inc (IMUX) - Business Payback Period|Price to Earnings Ratio Atara Biotherapeutics (ATRA)|Business Payback Period inflarx.de|X4 Pharmaceuticals - Price to Earnings Ratio|Market Price to Net Income Ratio ACET (Adicet Bio Inc.)|CELU: Price to Earnings Ratio|INmune Bio Inc - Market Price to Net Income Ratio|Barinthus Bio (BRNS) - Price to Earnings Ratio|Kezar Life Sciences Inc (KZR) - P/E Multiple|Price to Earnings Ratio SAB Biotherapeutics|akaritx.com - Market Cap to Net Income|P/E Multiple ENLV|QTTB (q32bio.com) - Company Value to Net Income|P/E Multiple GOVX (GeoVax Labs Inc)|P/E Multiple Edesa Biotech Corp EDSA|IBIO - Price to Earnings Ratio|Company Value to Net Income CARM (Carisma Therapeutics)|XTL Biopharmaceuticals Ltd. (XTLB) - Price to Earnings Ratio|Price to Earnings Ratio Bolt Biotherapeutics, Inc.|HCWB (HCW Biologics, Inc.) - P/E Multiple|P/E Multiple Aptevo|Price to Earnings Ratio AIM (AIM ImmunoTech Inc.)|ADTX (aditxt.com) - Company Value to Net Income|P/E Multiple GRI (GRI Bio)|Business Payback Period XORTX Therapeutics Inc (XRTX)|HIND - Price to Earnings Ratio|Revelation Biosciences Corp (REVB) - Price to Earnings Ratio|Indaptus Therapeutics (INDP) - Price to Earnings Ratio|Price to Earnings Ratio scinai.com|Price to Earnings Ratio CALI|P/E Multiple Affimed Therapeutics|Price to Earnings Ratio Allakos Inc. (ALLK)|hookipapharma.com - Price to Earnings Multiple|P/E Multiple IGMS (IGM Biosciences)|iteostherapeutics.com (ITOS) - Market Cap to Earnings|OCEA - Price to Earnings Ratio|Business Payback Period TC BioPharm (Holdings) Plc TCBP|THRD: P/E Multiple
